Washington: Vaccine maker Novawax (Novavax) has said its vaccine is highly effective against the corona virus epidemic and provides protection against all variants of the virus. This has been revealed in the major and final stage trials conducted in the US and Mexico.
The company has said that the vaccine is about 90 percent effective overall and preliminary data shows that it is safe. Although the demand for anti-corona vaccines in the Us has declined, more vaccines are needed worldwide. Novawax vaccine is easy to keep and carry and is expected to play an important role in increasing vaccine supply in developing countries.
The Serum Institute of India (SII), which is producing vaccines in India, will also be a partner in the manufacturing of Novavax. Novawax said it plans to get approval for the use of vaccines in the US, Europe and elsewhere by the end of September and will be able to produce 100 million doses a month by then. "Many of our early doses will go to low and middle income countries," Novawax Chief Executive Stanley Erk told the media.
Finance Ministry notifies concessional GST rate on COVID-related services
Delhi AIIMS to resume out-patient services in a phased manner from June 18 onwards
PM Modi addresses UN meeting, gave idea to improve barren land in Kutch